133928-64-0

Basic information

• Product Name: 2-Chloro-3-methyl-N-methyl-N-phenylisonicotinamide
• Synonyms: 2-Chloro-3-methyl-N-methyl-N-phenylisonicotinamide;2-Chloro-N,3-diMethyl-N-phenylisonicotinaMide
• CAS NO: 133928-64-0
• Molecular Formula: C₁₄H₁₃ClN₂O
• Molecular Weight: 260.71882
• Mol File: 133928-64-0.mol

Chemical Properties

• Boiling Point: 432.5±45.0 °C(Predicted)
• Appearance: /
• Density: 1.251±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 0.23±0.50(Predicted)
• CAS DataBase Reference: 2-Chloro-3-methyl-N-methyl-N-phenylisonicotinamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-3-methyl-N-methyl-N-phenylisonicotinamide(133928-64-0)
• EPA Substance Registry System: 2-Chloro-3-methyl-N-methyl-N-phenylisonicotinamide(133928-64-0)

Safety Data

• Hazardous Substances Data: 133928-64-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
2-Chloro-3-methyl-N-methyl-N-phenylisonicotinamide is used as a building block in the synthesis of various drugs and biologically active compounds. Its unique chemical structure allows for the creation of new molecules with potential therapeutic effects.
Used in Antitumor Applications:
In the field of oncology, 2-Chloro-3-methyl-N-methyl-N-phenylisonicotinamide is used as a potential antitumor agent. Its antitumor properties make it a candidate for further research into its effects on cancer cells and its potential role in cancer treatment.
Used in Antifungal Applications:
2-Chloro-3-methyl-N-methyl-N-phenylisonicotinamide also exhibits antifungal properties, making it a candidate for use in the development of antifungal drugs. This could be particularly beneficial in treating various fungal infections and combating drug-resistant strains.
Used in Drug Synthesis:
As a key intermediate in the synthesis of pharmaceuticals, 2-Chloro-3-methyl-N-methyl-N-phenylisonicotinamide is used to create a variety of drug molecules. Its versatility in chemical reactions allows for the development of new compounds with potential therapeutic applications.

Upstream product

• 80194-83-8 2-chloro-N-phenylisonicotinamide 
• 74-88-4 methyl iodide 

Downstream Products

• 851314-24-4 8-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-5-aza-spiro[2.5]oct-7-ene-7-carboxylic acid cyclopropyl-[2-(2-hydroxypropoxy)-3-methylpyridin-4-ylmethyl]amide 
• 787596-41-2 methyl 2-chloro-3-methyl-pyridine-4-carboxylate 
• 133928-73-1 2-chloro-3-methylisonicotinic acid 
• 790696-96-7 2-chloro-3-methyl-pyridine-4-carbaldehyde 

Relevant articles and documents

Heterocyclic-substituted nitrogen-containing six-membered heterocyclic derivative and preparation method and medical application thereof

The invention relates to a heterocyclic-substituted nitrogen-containing six-membered heterocyclic derivative, a preparation method thereof and application of the heterocyclic-substituted nitrogen-containing six-membered heterocyclic derivative as a PD-1/PD-L1 inhibitor. Specifically, the invention discloses a compound shown as a formula (I) or a pharmaceutically acceptable salt, a deuterated compound, a stereoisomer, a solvate and a prodrug thereof, and a preparation method and application of the compounds, and the definition of each group in the formula is detailed in the description and claims.

SUBSTITUTED BENZENE COMPOUNDS

The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

BICYCLONONENE DERIVATIVES

The invention relates to novel bicyclononene derivatives and the use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin.

BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS

The invention relates to novel bicyclononene derivatives of Formula (I); and the use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin.

DIAZABICYCLONONENE AND TETRAHYDROPYRIDINE DERIVATIVES WITH A NEW SIDE-CHAIN

The invention relates to novel bicyclic derivatives, and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the co

DIAZABICYCLONONENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS

The invention relates to novel derivatives and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, p

DIAZABICYCLONONENE AND TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS

The invention relates to novel bicyclic derivatives and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the com

DIAZABICYCLONONENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS

The invention relates to novel 3,9-diazabicyclo[3.3.1]nonene derivatives of formula (I), wherein Z is 0 or 1, one of m, n is 0 and the other is 1, and their use as inhibitors of renin.

TETRAHYDROPYRIDINE DERIVATIVES

The invention relates to novel tetrahydropyridine derivatives and use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin. (I) wherein X and Y represent independently hydrogen, fluorine or a methyl group; X and Y do not represent both hydrogen at the same time or X and Y may together form a cyclopropyl ring; W represents a phenyl or a heteroaryl, the heteroaryl ring being a six-membered and non-fused ring, the phenyl ring and the heteroaryl are substituted with V in position 3 or 4; A and B independently represent-O-;-S-;-SO-or-SO2-; U represents aryl or heteroaryl; T represents-CONR1-;-(CH2)pOCO-;-(CH2)pN(R1)CO-;-(CH2)p N(R1)SO2-;-COO-;-(CH2)pOCONR1-or-(CH2)pN(R2)CONR1-; R1 and R2 independently respresent hydrogen; lower alkyl; lower alkenyl; lower alkynil; cycloalkyl; aryl-lower alkyl, heteroaryl-lower alkyl or cycloalkyl-lower alkyl; Q represents lower alkylene or lower alkenylene; M represents hydrogen; cycloalkyl; aryl; heterocyclyl or heteroaryl:

Application of organolithium and related reagents in synthesis. Part 9. Synthesis and metallation of 4-chloropicolin- and 2-chloroisonicotinanilides. A useful method for preparation of 2,3,4-trisubstituted pyridines

The synthesis and metallation (nBuLi) of 4-chloropicolin- and 2-chloroisonicotinanilides (1) and (2) as a way of regiospecific transformation of picolinic and isonicotinic acids into 2,3,4-trisubstituted pyridines (9) and (10), is described. The anilide moiety (masking group) of the formed C3-substituted chloro-anilides (9) and (10) appeared to be effectively removable on acid hydrolysis.